James Ballance
Nessuna posizione attualmente
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stuart Green | M | 58 |
University of Bristol
| 6 anni |
Mohammad Sharif Ali Sharif Al-Zoubi | M | 61 |
University of Bristol
| 1 anni |
George Poste | M | 79 |
University of Bristol
| 3 anni |
Carolyn Christie | F | 65 |
University of Bristol
| 4 anni |
Michael McGuigan | M | - |
University of Bristol
| 4 anni |
John Whitebrook | M | - |
University of Bristol
| 3 anni |
Phil Taylor | M | - |
University of Bristol
| 4 anni |
Yusuf bin Jamil | M | 60 |
University of Bristol
| 4 anni |
Nick Fry | M | - |
University of Wales (Bangor)
| 4 anni |
Andrew Oliver Mullins | M | 60 |
University of Bristol
| 4 anni |
Alan R. Nicholl | M | - |
University of Bristol
| 4 anni |
Phil Ivey | M | - |
University of Bristol
| 4 anni |
Clive Banks | M | - |
University of Bristol
| 4 anni |
Donald Charles McQueen | M | 62 |
University of Bristol
| 4 anni |
James Greenwood | M | 60 |
University of Bristol
| 3 anni |
David Anthony Littlewood | M | 58 |
University of Bristol
| 3 anni |
Kay Nichols | F | - |
University of Bristol
| 3 anni |
Frederick Jones | M | - |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | - |
Andrew Mullins | M | - |
University of Bristol
| 4 anni |
David Maguire | M | - |
University of Bristol
| 3 anni |
Nigel Spray | M | - |
University of Bristol
| 3 anni |
Christine Whyte | M | - |
University of Bristol
| 3 anni |
Charles Edward Beck Bowman | M | 63 |
University of Bristol
| 4 anni |
Roger Blott | M | - |
University of Bristol
| 3 anni |
Sarah Brown | F | 60 |
University of Bristol
| 3 anni |
Daniel Newman | M | 64 |
University of Bristol
| 4 anni |
David B. Morris | M | 57 |
University of Bristol
| 4 anni |
Adam Hale | M | 59 |
University of Bristol
| 3 anni |
Rhodri Glyn Thomas | M | 71 |
University of Wales (Bangor)
| 4 anni |
Mark Gino Francois | M | 58 |
University of Bristol
| 4 anni |
Clive Stuart Brown | M | 64 |
University of Bristol
| 3 anni |
Matthew Tossell | M | - |
University of Wales (Bangor)
| 3 anni |
Roger Murphy | M | - |
University of Wales (Bangor)
| 4 anni |
Wai Man Chu | M | 59 |
University of Bristol
| 3 anni |
David Michael Foulds | M | - |
University of Bristol
| 4 anni |
Charles Edwardes-Ker | M | - |
University of Bristol
| 4 anni |
Michael Celano | M | 65 |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | 3 anni |
Mark Poole | M | 60 |
University of Bristol
| 4 anni |
Quintin Price | M | 63 |
University of Bristol
| 4 anni |
Edwin Harless | M | 77 |
Aventis Behring
| 3 anni |
Richard Cunningham | M | 64 |
University of Bristol
| 3 anni |
Michael Lindsell | M | 64 |
University of Bristol
| 4 anni |
Andrew McIver | M | 61 |
University of Bristol
| 4 anni |
Paul McGroary | M | 66 |
University of Wales (Bangor)
| 4 anni |
Robert Barker | M | 61 |
University of Bristol
| 4 anni |
Warren Tucker | M | 61 |
University of Bristol
| 4 anni |
Nick Bertolotti | M | 62 |
University of Bristol
| 4 anni |
Richard M. Campbell-Breeden | M | 62 |
University of Bristol
| 4 anni |
David Scott | M | 62 |
University of Bristol
| 4 anni |
Asish Xavier | M | - |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | 1 anni |
Royston Stephen Ferris | M | 64 |
University of Bristol
| 4 anni |
Frederick Jones | M | - |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | 3 anni |
Stephen Dewhurst | M | - |
University of Bristol
| 3 anni |
Henry Sallitt | M | 62 |
University of Bristol
| 3 anni |
Ray N. Simpson | M | - |
University of Bristol
| 4 anni |
Sally Caroline Powell | F | - |
University of Bristol
| 3 anni |
Michael Greville | M | - |
University of Bristol
| 4 anni |
David Roy Ettle | M | - |
University of Bristol
| 4 anni |
Mark John Tomlinson | M | - |
University of Wales (Bangor)
| 4 anni |
Timothy Moore | M | 62 |
Aventis Behring
| 4 anni |
Jeremy K. Llewelyn | M | - |
University of Bristol
| 4 anni |
Hang Fong Lo | M | 54 |
University of Bristol
| 3 anni |
T. Ben Hsu | M | - |
Aventis Behring
| 4 anni |
David Srodzinski | M | - |
University of Bristol
| 4 anni |
Alex Donnison | M | - |
University of Wales (Bangor)
| 4 anni |
Sean W. Lanigan | M | - |
University of Wales (Bangor)
| 1 anni |
Mohamed Nazir bin Abdul Razak | M | 58 |
University of Bristol
| 4 anni |
Wai Ha Tang | F | 60 |
University of Bristol
| 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 61 | 89.71% |
Stati Uniti | 7 | 10.29% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- James Ballance
- Contatti personali